Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
allo-APZ2-CVU for therapy-resistant chronic venous ulcer
2023-510162-27-00Phase 2Completed
- Sponsor
- RHEACELL
- Start
- Mar 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EBESANAR in stasis ulcer (4 arms), sponsored by RHEACELL. Primary endpoints: Complete wound closure at Week 18 persisting for at least 2 weeks and Adverse events. Started Mar 2024; status: completed.
02
Drugs
EBESANAR
03
Conditions
stasis ulcer
Beyond the preview
Go deeper on 2023-510162-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510162-27-00.